EPCAM and ovarian carcinoma: In another study, treatment of A2780 ovarian cancer cells with exosomes derived from three platinum-resistant derivatives of A2780 (C30, CP70, and C200) exhibited a considerable decrease in the expression of epithelial markers (E-cadherin, EpCAM, and dystroglycan) and an increase in the expression of mesenchymal markers (TWIST, vimentin, and paladin), and indicator of EMT phenotype that coincided with resistance to carboplatin [103].